Patents by Inventor Kathleen A. Boris-Lawrie

Kathleen A. Boris-Lawrie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
    Patent number: 5770428
    Abstract: This invention is directed toward novel replication competent retroviral expression vectors and particles containing a single chimeric viral genome composed of a simple retroviral (e.g., spleen necrosis virus ?SNV!) long terminal repeat (LTR), complex retroviral (e.g., Bovine Leukemia Virus ?BLV! or Human Immunodeficiency Virus ?HIV!) gag, pol, and env coding regions, complex retroviral cis-acting sequences (e.g., the encapsidation signal ?E!, primer binding site ?PBS!, polypurine tract ?PPT!, and att sites), and an RNA translational enhancer containing an internal ribosome entry site (IRES). These chimeric viral genomes express the BLV or HIV gag, pol, and env genes in a tax/rex- or tat-/rev-independent manner, respectively. Moreover, the inclusion of an IRES site in the modified viral genome facilitates the expression of the env gene products.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: June 23, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Kathleen A. Boris-Lawrie
  • More complex type retroviruses having mixed type LTR, and uses thereof
    Patent number: 5554524
    Abstract: Chimeric retroviral vectors were constructed containing the long terminal repeats (LTRs) from a simple retrovirus (e.g. spleen necrosis virus (SNV); murine leukemia virus (MLV)) devoid of the integration site (att) and more complex retroviral (e.g. bovine leukemia virus (BLV); human immunodeficiency virus (HIV)) cis-acting regulatory sequences (e.g. att; primer binding site (PBS); encapsidation site (E), and polypurine tract (ppt)) and coding regions. Cells transfected with these constructs produce replication competent retrovirus particles. These retroviral particles provide a source of viral antigens that can be employed in both diagnostic assays and as immunogens for the production of high-titer specific antisera.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: September 10, 1996
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Howard M. Temin, Kathleen A. Boris-Lawrie